Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 3
Submit an article Journal homepage
563
Views
16
CrossRef citations to date
0
Altmetric
Original Articles

Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis

Douglas TremblayTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ORCID Iconhttp://orcid.org/0000-0003-2584-6953
ORCID Icon,
Amber KingLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
,
Lihua LiDepartment of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Erin MoshierDepartment of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Alexander ColtoffTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Anita KoshyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Marina KremyanskayaTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Ronald HoffmanTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Michael J. MauroLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
,
Raajit K. RampalLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
&
John MascarenhasTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Correspondence[email protected]
 show all
Pages 660-667 | Received 03 Sep 2019, Accepted 23 Oct 2019, Published online: 12 Nov 2019

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange & Fleur Samantha Benghiat. (2022) Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology 27:1, pages 23-31.
Read now
James T. England & Vikas Gupta. (2022) Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis. Expert Opinion on Pharmacotherapy 23:15, pages 1677-1686.
Read now
Nina Lu, Chin Loon Neoh, Zhengying Ruan, Lei Zhao, Limei Ying, Xiaochang Zhang, Sai Chen & Linglong Xu. (2020) Essential Thrombocythaemia with Concomitant Waldenström Macroglobulinaemia: Case Report and Literature Review. OncoTargets and Therapy 13, pages 3431-3435.
Read now
Yizhou Peng, Li Meng, Xuemei Hu, Zhiqiang Han & Zhenya Hong. (2020) Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review. Infection and Drug Resistance 13, pages 3309-3316.
Read now

Articles from other publishers (12)

Chen Yang, Meaghan S. Cuerden, Wei Zhang, Melissa Aldridge & Lihua Li. (2023) Propensity score weighting with survey weighted data when outcomes are binary: a simulation study. Health Services and Outcomes Research Methodology.
Crossref
Iwona Hus, Agnieszka Szymczyk, Joanna Mańko & Joanna Drozd-Sokołowska. (2023) COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic. Biology 12:4, pages 545.
Crossref
Monia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, Luisa Verga, Federico Itri, Zdeněk Ráčil, Julio Dávila-Valls, Sonia Martín-Pérez, Jaap Van Doesum, Francesco Passamonti, Ghaith Abu-Zeinah, Francesca Farina, Alberto López-García, Giulia Dragonetti, Chiara Cattaneo, Maria Gomes Da Silva, Yavuz M. Bilgin, Pavel Žák, Verena Petzer, Andreas Glenthøj, Ildefonso Espigado, Caterina Buquicchio, Valentina Bonuomo, Lucia Prezioso, Stef Meers, Rafael Duarte, Rui Bergantim, Ozren Jaksic, Natasha Čolović, Ola Blennow, Martin Cernan, Martin Schönlein, Michail Samarkos, Maria Enza Mitra, Gabriele Magliano, Johan Maertens, Marie-Pierre Ledoux, Moraima Jiménez, Fatih Demirkan, Graham P. Collins, Alba Cabirta, Stefanie K. Gräfe, Anna Nordlander, Dominik Wolf, Elena Arellano, Raul Cordoba, Michaela Hanakova, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Giulia Limberti, Francesco Marchesi, Oliver A. Cornely & Livio Pagano. (2023) Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. Therapeutic Advances in Hematology 14, pages 204062072311547.
Crossref
Yoko Edahiro, Kohshi Ohishi, Akihiko Gotoh, Katsuto Takenaka, Hirohiko Shibayama, Takayuki Shimizu, Kensuke Usuki, Kazuya Shimoda, Masafumi Ito, Scott A. VanWart, Oleh Zagrijtschuk, Albert Qin, Hiroaki Kawase, Narihisa Miyachi, Toshiaki Sato, Norio Komatsu & Keita Kirito. (2022) Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. International Journal of Hematology 116:2, pages 215-227.
Crossref
Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, Claire Harrison, Steffen Koschmieder, Heinz Gisslinger, Alberto Álvarez-Larrán, Valerio De Stefano, Paola Guglielmelli, Francesca Palandri, Francesco Passamonti, Giovanni Barosi, Richard T Silver, Rüdiger Hehlmann, Jean-Jacques Kiladjian & Tiziano Barbui. (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. The Lancet Haematology 9:4, pages e301-e311.
Crossref
Annalisa Marcuzzi, Erika Rimondi, Elisabetta Melloni, Arianna Gonelli, Antonio Giacomo Grasso, Egidio Barbi & Natalia Maximova. (2022) New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib. Pharmaceuticals 15:3, pages 374.
Crossref
Daniele Cattaneo & Alessandra Iurlo. (2021) Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors. Frontiers in Immunology 12.
Crossref
Pierre‐Luc Mouchel, Charlotte Syrykh, Camille Laurent, Suzanne Tavitian & Martin Gauthier. (2020) First case of classical Hodgkin‐like EBV ‐positive lymphoproliferative disorder under ruxolitinib therapy . American Journal of Hematology 96:6, pages 755-756.
Crossref
Klara Klein, Dagmar Stoiber, Veronika Sexl & Agnieszka Witalisz-Siepracka. (2021) Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?. Cancers 13:11, pages 2611.
Crossref
Anna Ravn Landtblom, Therese M-L Andersson, Paul W Dickman, Karin E Smedby, Sandra Eloranta, Nurgul Batyrbekova, Jan Samuelsson, Magnus Björkholm & Malin Hultcrantz. (2020) Risk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patients. Leukemia 35:2, pages 476-484.
Crossref
Giacomo Coltro, Giuseppe G. Loscocco & Alessandro M. Vannucchi. 2021. Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A. Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A 1 69 .
Douglas Tremblay & John Mascarenhas. (2020) Novel Therapies in Polycythemia Vera. Current Hematologic Malignancy Reports 15:2, pages 133-140.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.